FDA Submission Expected This Summer - Invest Before It Happens
This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.
| Open | 170.62 | Prev Close | 170.59 |
| High | 171.49 | Low | 170.19 |
| Volume | 11,247 | Volume (Avg) | 8,444 |
| 52 Week High | 172.18 | 52 Week Low | 138.38 |
| Market Cap | 411.5B | PE Ratio | 18.27 |
General
| Name | Johnson & Johnson |
| Ticker | JNJ |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 138,100 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Highlights
| Analyst Target | 176.45 |
| Market Cap | 411,488,800,000 |
| PE Ratio | 18.27 |
| PEG Ratio | 1.04 |
| EBITDA | 30,254,999,552 |
Valuation
| Trailing PE | 18.24 |
| Forward PE | 15.90 |
| Price/Sales (Trailing 12 Mt.) | 4.54 |
| Price/Book (Most Recent Quarter) | 5.24 |
Technicals
| Beta | 0.38 |
| 52 Week High | 172.18 |
| 52 Week Low | 138.38 |
| 50 Day Average | 7.54% |
| 200 Day Average | 9.72% |
Dividend
Johnson & Johnson pays out a dividend of $5.06 per share, with a dividend yield of 2.96%.
JNJ's next dividend payment will be made to shareholders on September 9, 2025.
They pay out 84.80% of their earnings out as a dividend.
Recent Dividends
| Sep 9, 2025 | $1.30 |
| Jun 10, 2025 | $1.30 |
| Mar 4, 2025 | $1.24 |
| Dec 10, 2024 | $1.24 |
| Sep 10, 2024 | $1.24 |
| Jun 4, 2024 | $1.24 |
| Mar 5, 2024 | $1.19 |
| Dec 5, 2023 | $1.19 |
| Sep 7, 2023 | $1.19 |
Paula Deen has abruptly closed the Savannah restaurant that launched her to Food Network fame
SAVANNAH, Ga. (AP) — Former Food Network star Paula Deen announced Friday the abrupt closure of the Savannah restaurant that launched her to fame with its menu of fried chicken, banana pudding and other indulgent Southern dishes.
Marjorie Taylor Greene Increases These 2 Stocks In Portfolio, Including This AI Name Up Over 100% YTD
Marjorie Taylor Greene has bought stocks multiple times in 2025 and her recent disclosure adds to one of the stocks that drew the biggest red flags in 2025.
Back This Medical AI Tech - Ad
You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.
McDonald's posts better-than-expected sales as chicken strips, Minecraft meal drive traffic
Hot products like a “Minecraft”-themed meal helped McDonald’s turn around its sagging sales in the second quarter.
Senate committee advances Trump nominee to lead cybersecurity agency that protects election systems
NEW YORK (AP) — A U.S. Senate committee voted Wednesday to advance President Donald Trump’s pick to lead the agency that secures the nation’s critical infrastructure, .
Is Your Capital Following a Real Strategy? - Ad
Trade with $100K-$200K funded capital-no manual trading. Our AI system skips charts, eliminates stress, and lands you funding. Thousands passed prop challenges with us. Apply now, book a call, and have $10K ready.
How Ethereum Treasury Companies Beat Out ETFs: Standard Chartered
Ethereum (CRYPTO: ETH) treasury companies are rapidly emerging as a compelling alternative to U.S.-listed spot Ethereum ETFs, according to a Wednes
Denny's CEO Asks Potential Hires Only Two Questions But Reveals It 'Doesn't Matter What The Questions Are' — Here's Why
Denny's CEO Kelli Valade shares her hiring strategy of looking for red flags and self-awareness through thoughtful questions, not just answers.
Tap Into the $65B 'Shroom Boom' - Ad
People are rapidly discovering how mushrooms can enhance brain function, gut health, immunity, and more. The only thing holding them back? A simple way to grow them. Hypha Labs built a compact countertop device to solve exactly that.
Dan Ives Raises Palantir Price Target, Sees 24% Upside On 'Hyper Growth Demand' — Stock Jumps Nearly 6% In Tuesday Pre-Market
Wedbush analyst Dan Ives raised his price target on Palantir Technologies Inc. (NYSE: PLTR) to $200, citing "hyper growth demand" and "off the charts" commercial expansion.
Edmunds small luxury SUV test: 2025 Acura ADX vs 2025 BMW X1
The is all-new this year, and it takes its place as Acura’s smallest and least expensive crossover SUV. If you think Acura’s RDX or MDX are too big or too expensive, the entry-level ADX could very well satisfy.
Trading Isn't Your Job. Let the System Handle It. - Ad
HiveMind AI handles trades for you-based on logic, not gut instinct. Built by pro traders. Runs 24/7. No emotions. No second-guessing. Want to deploy capital smarter?
Meta Just Paid $250M To Lure This 24-year-old AI Whiz Kid: A Strategic Move Or A Power Play?
Meta Platforms has reportedly invested a staggering $250 million to secure the talents of 24-year-old AI prodigy, Matt Deitke.
Trump pressures China and India to stop buying cheap Russian oil
U.S. President Donald Trump is pushing and to stop buying oil from Russia and helping fund the .
Back the Biotech Company Unlocking Mushroom Health Benefits for All - Ad
Functional mushrooms can boost mental, gut, and immune health-but people can't grow them at home. One company is making it easy with a patent-pending kitchen device. Think Nespresso, but for mushrooms. The functional mushroom market is projected to nearly double by 2030.
Firefly Aerospace Hikes IPO Price Range, Eyes Over $6 Billion Valuation
Firefly Aerospace increases the expected price range for its upcoming IPO.
Economists Warn US Close To 'Stall Speed' And Could 'Tip Over Into Recession' On Disappointing Jobs Report
The July Jobs report by the U.S. Bureau of Labor Statistics, released on Friday, is raising concerns among economists, who warn that the latest data and sharp downward revisions point to a labor market that is losing momentum and potentially edging toward a recession.
Better Than Bitcoin? (Top Crypto for Less Than $1) - Ad
Over the past 15 years, Bitcoin has outperformed stocks, bonds, and every other asset you could've bought. 2025 is already shaping up to be another banner year, with Bitcoin recently hitting a new all-time high. But there's a better way to profit from this new crypto rally. Most people don't know about it... and yet it's returned over 1,000% in 4 months. This could be the #1 way to invest in crypto right now.
Cathie Wood's Wednesday Moves: Ark Dumps Bitcoin-Heavy Block Again, Doubles Down On AMD's AI Chip Rally (CORRECTED)
Editor’s Note: The headline has been corrected from the original version to ensure accuracy and clarity
Milei vetoes pension and disability spending increases, citing fiscal deficit pledge
BUENOS AIRES, Argentina (AP) — Libertarian on Monday vetoed an attempt to increase spending on pensions in and a law expanding protections for people with disabilities, saying the legislation would have undermined his flagship pledge to eliminate the country’s chronic fiscal deficit before October’s midterm elections.
The Surprising New Date That Could Fuel the AI Boom - Ad
Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.
BlackRock's New ETF BILT Bets On $68 Trillion Boom, But Most Investors Are Missing It
BlackRock debuts first actively managed infrastructure ETF (BILT), highlighting growing interest in this sector. Offers diversity and growth potential.
BYD Surpasses Tesla In Fortune Global 500 List Amid Sales Slump For Elon Musk's EV Giant
BYD surpassed Tesla on Fortune Global 500 list, with BYD at #92 and Tesla at #102. BYD's growth in global markets may be a factor.
Smarter Capital. No Screens. No Noise. - Ad
HiveMind AI handles trades for you-based on logic, not gut instinct. Built by pro traders. Runs 24/7. No emotions. No second-guessing. Want to deploy capital smarter?
Could Trump Accounts Turn American Babies Into Tomorrow's Millionaires? Here's What Experts Say
A new federal savings initiative, known as "Trump accounts," signed into law by President Donald Trump, could significantly alter the financial future of millions of American children.
Why Is Donald Trump Ignoring Elon Musk's Call For 'Phase 2' Of The Epstein Files?
Musk's post questioning Trump's unfulfilled promise of Epstein-related disclosures reignites tensions over transparency in politics and tech.
How to Hack a $1.3T Market - Ad
Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.
Bitcoin, Ethereum, Dogecoin, XRP Mirror Stocks Decline: Analyst Touts 'Buy The Dip' Tagline
Leading cryptocurrencies fell alongside stocks on Tuesday as investors priced in new tariffs and weaker-than-expected economic data.
Apple Surges After-Hours As Q3 Earnings Crush Estimates, iPhone And Services Lead Growth
Apple Inc. shares jumped 2.42% in after-hours trading on Thursday, reaching $212.59, after the iPhone maker delivered third-quarter results that significantly exceeded Wall Street expectations.
FDA Submission Expected This Summer - Invest Before It Happens - Ad
This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.
FOMC Meeting Preview: Will Jerome Powell Accelerate The Bitcoin, Ethereum, XRP Bull Run?
Bitcoin (CRYPTO: BTC) and other cryptocurrencies continue to trade sideways ahead of Wednesday’s Federal Open Market Committee meeting, though pundits expect volatility to pick up soon.
Cathie Wood Goes On A $20M Bitmine Immersion Bargain Hunt As Ark Trims Robinhood And Palantir Stakes
On Monday, Cathie Wood-led Ark Invest made significant trades, including a notable purchase of Bitmine Immersion Technologies Inc. (BMNR) shares.
Back This Medical AI Tech - Ad
You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.
Pakistan urges global social media platforms to block accounts run by banned militant groups
ISLAMABAD (AP) — on Friday urged to take action to block hundreds of accounts allegedly run by outlawed militant groups that Islamabad claims spread propaganda and glorify insurgents in the South Asian country.
Pilot arrested on child sex abuse material charges after landing at San Francisco airport
SAN FRANCISCO (AP) — A pilot was arrested aboard a Delta Air Lines flight and federal agents took him into custody from the cockpit after the plane landed at San Francisco International Airport.
Is Your Capital Following a Real Strategy? - Ad
Trade with $100K-$200K funded capital-no manual trading. Our AI system skips charts, eliminates stress, and lands you funding. Thousands passed prop challenges with us. Apply now, book a call, and have $10K ready.
Polymarket Crypto Bettors See 50% Chance Of Fed Rate Cut In September Meet Amid Escalating Trump-Jerome Powell Clash
Cryptocurrency bettors are pricing in a 50% chance that the Federal Reserve will enact the first interest rate cut of 2025 during the upcoming September meeting.
TransMedics Group Stock Jumps On Q2 Earnings Beat, Company Raises 2025 Outlook
TransMedics Group shares are rising in Wednesday's after-hours session after the company reported financial results for the second quarter.
Tap Into the $65B 'Shroom Boom' - Ad
People are rapidly discovering how mushrooms can enhance brain function, gut health, immunity, and more. The only thing holding them back? A simple way to grow them. Hypha Labs built a compact countertop device to solve exactly that.
US Passport Slides To Lowest Rank In Decades As Visa Waiver Deals Stall
US passport slips to 10th place on Henley Passport Index, down from 1st in 2014. Analysts cite stricter vetting and stalled reciprocity talks.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.